VIVEX BIOLOGICS GROUP, INC.
ATLANTA, GA

VIVEX BIOLOGICS GROUP, INC., Atlanta
VIVEX BIOMEDICAL, INC.

0 cases of disease transmission Vivex strives to create treatment options and solutions that will improve clinical, surgical, and therapeutic patient care through innovation. Under the guidance of experienced and successful business professionals, Vivex tasks the brightest minds from the medical and material science industries to explore new and different ways to help others. Vivex works with services that are committed to providing care and compassion to donor families while inspiring communities to share life through their donation. Partnering with families in the prospect of regenerative options, Vivex assures appropriate options are available to support regeneration and translation of their gifts. ) has been a worldwide leader in bone transplantation and tissue banking. UMTB was founded in 1970 as the U.S. Navy Tissue Bank curtailed its service to civilian patients. Recognizing the potential therapeutic loss attending this change, Theodore I. Malinin, MD, trained and experienced in tissue banking at the U.S. Navy Tissue Bank Naval Medical Research Institute, adopted the protocols and tissue banking techniques used by this organization in founding the University of Miami Tissue Bank. By the 1990s, the University of Miami Tissue Bank was not only one of the oldest, but recognized as one of the largest and most well-respected tissue banks in the country. UMTB has assisted in the organization of new tissue banks throughout the United States and abroad. It has also provided training for personnel from other tissue banks in the U.S. and foreign countries and for surgeons interested in bone transplantation and tissue banking. H. Thomas Temple, MD, joined the University of Miami Tissue Bank in 1998. As a world leader in the field of Musculoskeletal Oncology, Dr. Temple remains an enthusiastic advocate of the proposition that clinical challenges respond to therapeutic solutions. With a reputation for his clinical insight and medical innovation, his patient care initiatives offer novel treatments that are unmatched in both novelty and empathy. As Chief Medical Officer for Vivex, his assurances matching quality and safety serve as impeccable guides to biologic product development. In 2014, Vivex Biomedical Inc. acquired UMTB, building on UMTB’s strong history, quality, and technology while advancing UMTB to become an industry leader in regenerative medicine. Today, Vivex focuses on core products and new technologies to meet the ever-growing biologic needs of surgeons and patients while continuing our 45-year history of serving and honoring both tissue donors and recipients. Together, Vivex and UMTB have distributed more than 2 million tissue allografts to 18 countries worldwide to better serve the needs of patients. We are constantly striving for creative treatment options and solutions to progress clinical, surgical, and therapeutic patient care by expanding industry knowledge and capability. Under the guidance of experienced and successful business professionals, we assemble the brightest minds from medical and material science industries to explore new and different ways to help others. We are constantly striving for creative treatment options and solutions to progress clinical, surgical, and therapeutic patient care by expanding industry knowledge and capability. Under the guidance of experienced and successful business professionals, we assemble the brightest minds from medical and material science industries to explore new and different ways to help others. Ellis serves as the CEO and Chairman of Ellis Capital, a consulting and investment firm primarily focused on the media, technology, healthcare, and fintech industries. Ellis primarily manages acquisitions, strategic relationships, and fund raising for his companies but has also been integrally involved in sales, operations, and strategic planning. He has managed multiple high growth companies and achieved significant returns for his investors. Ellis holds an MBA from the Darden Graduate School of Business Administration at UVA and a BA in Economics from the University of Virginia. Tracy S. Anderson has established an impressive career in the medical market by integrating his expertise as a skilled surgical technician with his corporate experience. A graduate of the University of Georgia, Anderson began working in the medical industry as a Cardiopulmonary Systems Specialist with Baxter Healthcare. After Baxter, he helped develop two intraocular lens companies, Ioptex, Inc. and Chiron, from the ground up. In 2002, Mr. Anderson founded Atlanta based T2MED, Inc., one of the Southeast’s most innovative private companies in the growing spinal device market. In 2008, Anderson merged T2 into Amendia, Inc., as one of its founding partners. With Anderson as the President of its Sales and Marketing group, Amendia grew to over $85 MM in sales before being acquired by private equity for $190 MM. In December of 2012, Anderson licensed a unique stem cell lineage from the University of Miami for potential use in general orthopaedics. In March of 2013, Vivex Biomedical was spun out from Amendia as a freestanding entity. In November of 2013, Anderson was instrumental in the acquisition of the University of Miami Tissue Bank, the oldest and one of the most prestigious human tissue facilities in the world. UMTB immediately became a fully owned subsidiary of Vivex Biomedical, Inc. Tim Ganey is Director of Orthopedic Research and Technology Development at the Atlanta Medical Center. He is also the recent President of co.don Tissue Engineering, a subsidiary of co.don AG. He has been published extensively in peer review journals and a lecturer at a variety of scientific meetings both domestically and overseas. Tim holds a B.S./B.A. degree at the University of Illinois and a Ph.D. degree at the University of South Florida. He is a member of eleven professional societies including the Orthopedic Research Society and the American Association for the Advancement of the Sciences. He has also been honored by various professional and business organizations, most recently as the 2000 winner of the Outstanding Research Award, Sofamor-Danek Award, Australian Spine Society. Further Tim is an Editorial Reviewer for industry publications including BioDrugs, Journal of Pediatric Orthopedics, Tissue Engineering, Journal of Shoulder and Elbow Surgery. Tim and his wife have four children and reside in Atlanta, Georgia. He is active in civic affairs including Paint Your Heart Out, Tampa and the Gulf Coast Life Science Initiative.

KEY FACTS ABOUT VIVEX BIOLOGICS GROUP, INC.

Company name
VIVEX BIOLOGICS GROUP, INC.
Status
Active
Filed Number
F15000002701
FEI Number
46-1175674
Date of Incorporation
June 22, 2015
Age - 10 years
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
http://vivexbiomedical.com
Phones
(888) 684-7783

VIVEX BIOLOGICS GROUP, INC. NEAR ME

Principal Address
3200 Windy Hill Road S.E. Suite 1650-W,
Atlanta,
GA,
30339,
US

See Also

Officers and Directors

The VIVEX BIOLOGICS GROUP, INC. managed by the three persons from Atlanta on following positions: Secr, Dire

Rey Pascual

Position
Secr Active
From
Atlanta, GA, 30339

Tracy Anderson

Position
Dire Active
From
Atlanta, GA, 30339

Jim Price

Position
Dire Active
From
Atlanta, GA, 30339





Registered Agent is CORPORATE CREATIONS NETWORK, INC.

Address
801 US HIGHWAY 1, NORTH PALM BEACH, FL, 33408

Events

August 1, 2019
NAME CHANGE AMENDMENT
July 2, 2019
NAME CHANGE AMENDMENT

Annual Reports

2023
March 20, 2023
2022
March 9, 2022